Compare Mesoblast Limited (MESO) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Prudential PLC — how do they compare? Mesoblast Limited trades at $14.28 (market cap $1.75B), while Prudential PLC trades at $23.94 (market cap $28.84B). The key difference: Prudential PLC is far larger — about 16.5× Mesoblast Limited's market cap, and Prudential PLC pays a 2.33% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Prudential PLC for 119 Days on average.
| MESO | PUK | |
|---|---|---|
Market Cap | $1.75B | $28.84B |
Volume | 239,027 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $20.96 | $33.61 |
52-Week Low | $13.19 | $23.54 |
Typical Hold Time | 15 Days | 119 Days |
Enterprise Value | $1.83B | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Prudential (PUK) trades at $23.87, up 1.38% with mixed technical signals showing bearish moving averages but oversold RSI levels. Fundamentally, the company demonstrates strong revenue growth from $16.2B in 2024 to $27.4B in 2025, with consistent profitability margins above 12%. Recent strategic moves include exiting emerging markets and focusing on core insurance operations while implementing a $3 billion capital rotation plan.
The outlook remains cautiously optimistic with 50% analyst buy ratings, though technical indicators suggest near-term pressure. Key risks include execution of strategic transitions and emerging market exposure reductions. The stock presents value characteristics with an 8.4 P/E ratio while maintaining dividend distributions, though investors should monitor earnings consistency after recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
